Zydus Cadila gets final approval from USFDA for Fulvestrant Injection

30 Jul 2021 Evaluate

Zydus Cadila has received final approval from the USFDA to market Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Pre-filled Syringe (USRLD: Faslodex Injection). Fulvestrant injection is used alone or in combination with other drugs to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause.

The drug will be manufactured at the group’s formulation manufacturing facility at the Zydus Biologics, Ahmedabad. The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

887.50 -9.10 (-1.01%)
29-Jan-2026 13:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1597.90
Dr. Reddys Lab 1200.00
Cipla 1319.40
Zydus Lifesciences 887.50
Lupin 2120.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×